Trial Profile

A Double Dummy, Double-blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PUR 3100 (Primary) ; Dihydroergotamine mesilate; Dihydroergotamine mesilate; Dihydroergotamine mesilate
Indications Migraine
Focus Adverse reactions; Pharmacokinetics
Sponsors Pulmatrix

Most Recent Events

15 May 2024 Results published in the Journal of Head and Face Pain.
15 May 2024 Results presented in a Pulmatrix media release.
11 Jul 2023 According to Pulmatrix media release, the results from this study were presented at the American Headache Society 65th Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com